O-GlcNAc signalling: implications for cancer cell biology - PubMed (original) (raw)
Review
O-GlcNAc signalling: implications for cancer cell biology
Chad Slawson et al. Nat Rev Cancer. 2011.
Abstract
O-GlcNAcylation is the covalent attachment of β-D-N-acetylglucosamine (GlcNAc) sugars to serine or threonine residues of nuclear and cytoplasmic proteins, and it is involved in extensive crosstalk with other post-translational modifications, such as phosphorylation. O-GlcNAcylation is becoming increasing realized as having important roles in cancer-relevant processes, such as cell signalling, transcription, cell division, metabolism and cytoskeletal regulation. However, currently little is known about the specific roles of aberrant O-GlcNAcylation in cancer. In this Opinion article, we summarize the current understanding of O-GlcNAcylation in cancer and its emerging functions in transcriptional regulation at the level of chromatin and transcription factors.
Figures
Figure 1. _O_-GlcNAc modifies the transcriptional machinery
In this inverted pyramid diagram, the transcription-regulating proteins that are modified by β-D-_N_-acetylglucosamine (GlcNAc; G) are shown. In addition to its catalytic role, _O_-linked _N_-acetylglucosamine transferase (OGT; red ovals) interacts with numerous transcription-regulating proteins. Starting from the bottom, histones are dynamically modified by _O_-GlcNAc; furthermore, the carboxy-terminal domain of RNA polymerase II (RNA Pol II), as well as the basal transcription factors (purple ovals) are also modified by _O_-GlcNAc. Many of the transcription-activating and transcription-repressing complexes (yellow circles) that contain histone-modifying enzymes, such as histone methyltransferases, histone acetytransferases and histone deacetylases, also interact with OGT, suggesting that OGT is an integral unit in the regulation of the histone code. Finally, many transcription factors (light blue circles) are modified by _O_-GlcNAc. Together, the collected data from many laboratories have strongly confirmed the regulation of gene transcription by _O_-GlcNAcylation. CEBPβ, CCAAT/enhancer-binding protein-β; CREB1, cyclicAMP-responsive element-binding protein 1; CRTC2, CREB-regulated transcription coactivator 2; FOXO, forkhead box protein O family; HCF1, host cell factor 1; MSL, male-specific lethal; NFAT, nuclear factor of activated T cells; NSL, nonspecific lethal; PDX1, pancreas/duodenum homeobox protein 1; PGC1α: peroxisome proliferator-activated receptor-γ co-activator 1α; PH, Polyhomeotic protein; TBP, TATA-box-binding protein.
Figure 2. Histone _O_-GlcNAcylation increases after stress
After a cellular stress event, histone _O_-GlcNAcylation (the covalent attachment of β-D-_N_-acetylglucosamine (GlcNAc) sugars to serine or threonine residues of proteins; green dots) increases, and this is correlated with an increase in DNA compaction. Histone _O_-GlcNAcylation is catalysed by _O_-GlcNAc transferase (OGT) via the addition of a GlcNAc moiety from UDP-GlcNAc.
Figure 3. Regulation of transcription factors by _O_-GlcNAc
a | The tumour suppressor p53 associates with the protein MDM2, which keeps p53 at low levels in cells by promoting its degradation. Phosphorylation (P) at Thr155 stimulates the rapid degradation of p53, and _O_-GlcNAcylation (the covalent attachment of β-D-_N_-acetylglucosamine (GlcNAc) sugars to serine or threonine residues of nuclear and cytoplasmic proteins; G) at Ser149 disrupts MDM2 binding and promotes p53 stability. Mutations abolishing _O_-GlcNAc on p53 enhances degradation. b | In quiescent cells, the oncoprotein MYC is _O_-GlcNAcylated at Thr58. Upon growth signals, the _O_-GlcNAc modification is rapidly removed, and the protein is phosphorylated at Ser62. This site is a priming site for glycogen synthase kinase 3β (GSK3β), which can then phosphorylate Thr58, leading to the rapid degradation of MYC. Numerous solid tumours have mutations at Thr58, which promotes increased MYC stability and altered gene transcription. Inhibition of GSK3β by lithium chloride (LiCl) or mutations at Ser62 increases _O_-GlcNAcylation at Thr58.
Similar articles
- O-GlcNAc signaling in cancer metabolism and epigenetics.
Singh JP, Zhang K, Wu J, Yang X. Singh JP, et al. Cancer Lett. 2015 Jan 28;356(2 Pt A):244-50. doi: 10.1016/j.canlet.2014.04.014. Epub 2014 Apr 24. Cancer Lett. 2015. PMID: 24769077 Free PMC article. Review. - Cross talk between O-GlcNAcylation and phosphorylation: roles in signaling, transcription, and chronic disease.
Hart GW, Slawson C, Ramirez-Correa G, Lagerlof O. Hart GW, et al. Annu Rev Biochem. 2011;80:825-58. doi: 10.1146/annurev-biochem-060608-102511. Annu Rev Biochem. 2011. PMID: 21391816 Free PMC article. Review. - Emerging Role of Protein O-GlcNAcylation in Liver Metabolism: Implications for Diabetes and NAFLD.
Xie Z, Xie T, Liu J, Zhang Q, Xiao X. Xie Z, et al. Int J Mol Sci. 2023 Jan 21;24(3):2142. doi: 10.3390/ijms24032142. Int J Mol Sci. 2023. PMID: 36768465 Free PMC article. Review. - Cross-talk between GlcNAcylation and phosphorylation: roles in insulin resistance and glucose toxicity.
Copeland RJ, Bullen JW, Hart GW. Copeland RJ, et al. Am J Physiol Endocrinol Metab. 2008 Jul;295(1):E17-28. doi: 10.1152/ajpendo.90281.2008. Epub 2008 Apr 29. Am J Physiol Endocrinol Metab. 2008. PMID: 18445751 Free PMC article. Review. - Elevated O-GlcNAcylation promotes gastric cancer cells proliferation by modulating cell cycle related proteins and ERK 1/2 signaling.
Jiang M, Qiu Z, Zhang S, Fan X, Cai X, Xu B, Li X, Zhou J, Zhang X, Chu Y, Wang W, Liang J, Horvath T, Yang X, Wu K, Nie Y, Fan D. Jiang M, et al. Oncotarget. 2016 Sep 20;7(38):61390-61402. doi: 10.18632/oncotarget.11359. Oncotarget. 2016. PMID: 27542217 Free PMC article.
Cited by
- Protein Substrates Engage the Lumen of O-GlcNAc Transferase's Tetratricopeptide Repeat Domain in Different Ways.
Joiner CM, Hammel FA, Janetzko J, Walker S. Joiner CM, et al. Biochemistry. 2021 Mar 23;60(11):847-853. doi: 10.1021/acs.biochem.0c00981. Epub 2021 Mar 12. Biochemistry. 2021. PMID: 33709700 Free PMC article. - O-Linked N-Acetylglucosamine (O-GlcNAc) Transferase and O-GlcNAcase Interact with Mi2β Protein at the Aγ-Globin Promoter.
Zhang Z, Costa FC, Tan EP, Bushue N, DiTacchio L, Costello CE, McComb ME, Whelan SA, Peterson KR, Slawson C. Zhang Z, et al. J Biol Chem. 2016 Jul 22;291(30):15628-40. doi: 10.1074/jbc.M116.721928. Epub 2016 May 26. J Biol Chem. 2016. PMID: 27231347 Free PMC article. - Prognostic relevance of the hexosamine biosynthesis pathway activation in leiomyosarcoma.
Tolwani A, Matusiak M, Bui N, Forgó E, Varma S, Baratto L, Iagaru A, Lazar AJ, van de Rijn M, Przybyl J. Tolwani A, et al. NPJ Genom Med. 2021 May 3;6(1):30. doi: 10.1038/s41525-021-00193-w. NPJ Genom Med. 2021. PMID: 33941787 Free PMC article. - Protein glycosylation in cancer.
Stowell SR, Ju T, Cummings RD. Stowell SR, et al. Annu Rev Pathol. 2015;10:473-510. doi: 10.1146/annurev-pathol-012414-040438. Annu Rev Pathol. 2015. PMID: 25621663 Free PMC article. Review. - Down-regulation of OGT promotes cisplatin resistance by inducing autophagy in ovarian cancer.
Zhou F, Yang X, Zhao H, Liu Y, Feng Y, An R, Lv X, Li J, Chen B. Zhou F, et al. Theranostics. 2018 Oct 6;8(19):5200-5212. doi: 10.7150/thno.27806. eCollection 2018. Theranostics. 2018. PMID: 30555541 Free PMC article.
References
- Torres CR, Hart GW. Topography and polypeptide distribution of terminal N-acetylglucosamine residues on the surfaces of intact lymphocytes. Evidence for O-linked GlcNAc. J. Biol. Chem. 1984;259:3308–3317. - PubMed
- Hart GW, Housley MP, Slawson C. Cycling of O-linked β-N-acetylglucosamine on nucleocytoplasmic proteins. Nature. 2007;446:1017–1022. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- R01 CA042486-28/CA/NCI NIH HHS/United States
- R01 DK061671-09/DK/NIDDK NIH HHS/United States
- P20 RR024214/RR/NCRR NIH HHS/United States
- P20RR024214/RR/NCRR NIH HHS/United States
- R01 CA042486/CA/NCI NIH HHS/United States
- R37 HD013563/HD/NICHD NIH HHS/United States
- R01 DK061671/DK/NIDDK NIH HHS/United States
- R37 HD013563-30/HD/NICHD NIH HHS/United States
- R01 DK61671/DK/NIDDK NIH HHS/United States
- P30 DK079637/DK/NIDDK NIH HHS/United States
- R24 DK084949/DK/NIDDK NIH HHS/United States
- R24 DK084949-01/DK/NIDDK NIH HHS/United States
- R01 CA42486/CA/NCI NIH HHS/United States
- N01‑HV‑00240/HV/NHLBI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources